Cite
HARVARD Citation
Queirolo, P. et al. (n.d.). 3346 BeyPro1: a Phase II single-arm study for the treatment after recurrence of advanced melanoma patients harboring the V600BRAF mutation and pretreated with Vemurafenib, with the association of Vemurafenib plus Fotemustine. European journal of cancer. pp. S683-. [Online].